Related Experiment Video
Updated: Apr 28, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
17.0K
Molecular biomarkers in interstitial lung diseases
Angelo De Lauretis1, Elisabetta A Renzoni
1Interstitial Lung Disease Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK, angelo.delauretis@gmail.com.
Molecular Diagnosis & Therapy
|June 18, 2014
Summary
Interstitial lung diseases (ILD) require accurate diagnosis for proper management. This review explores promising blood and lung tissue biomarkers for ILD, addressing current challenges and future research directions.
Area of Science:
- Pulmonology
- Biomarker Discovery
- Translational Medicine
Background:
- Interstitial lung diseases (ILD) present diverse clinical features, complicating diagnosis and management.
- Idiopathic pulmonary fibrosis (IPF) management differs from immunologically driven ILDs, like those in connective tissue diseases.
- Accurate diagnosis and patient selection are crucial for prognostication and timely treatment.
Purpose of the Study:
- To review validated and emerging biomarkers for interstitial lung diseases (ILD).
- To explore biomarkers in peripheral blood and lung tissue for ILD diagnosis and prognosis.
- To discuss current challenges and future directions in ILD biomarker research.
Main Methods:
- Literature review of studies investigating ILD biomarkers.
- Focus on high-throughput techniques and multi-parametric panels.
- Analysis of biomarkers in peripheral blood and lung tissue.
Main Results:
- No ILD biomarkers are currently in clinical practice, highlighting an unmet need.
- Advancements in biomarker research are evident, driven by new technologies.
- Selected validated and promising biomarkers in blood and tissue are discussed.
Conclusions:
- Validated non-invasive biomarkers are needed for ILD diagnosis, prognostication, and management.
- Ongoing research shows progress in identifying and applying ILD biomarkers.
- Future directions involve refining biomarker panels and clinical integration for improved patient care.
